TSG-6 promotes healing of critical-sized bone defects in mice

Tumor necrosis factor-stimulated gene 6 (TSG-6) is recognized for its anti-inflammatory and pro-regenerative properties in various inflammatory conditions, including peritonitis, arthritis, traumatic brain injury, and corneal as well as skin wound healing. However, its regenerative role in bone metabolism and repair remains largely unexplored. This study aimed to address this gap. We observed an increased expression of <i>Tnfaip6</i> (<i>Tsg-6</i>) during early osteogenic differentiation of murine mesenchymal stem cells (mMSCs). Silencing <i>Tnfaip6</i> significantly impaired osteogenic differentiation, as indicated by reduced alkaline phosphatase activity and downregulation of key osteogenic marker genes. RNA-seq analysis of <i>Tnfaip6</i>-deficient mMSCs revealed decreased expression of several genes that are critical for bone formation and healing, including matrix metallopeptidase 13, decorin, membrane metallopeptidase, and integrin binding sialoprotein. Conversely, gremlin 1, a known inhibitor of osteoblastogenesis, was significantly upregulated. To investigate the <i>in vivo</i> relevance, we assessed the effects of locally delivered recombinant TSG-6 (rTSG-6), embedded in a collagen gel, on bone regeneration in a 1.5 mm critical-sized femoral defect model in male C57BL/6J mice. Treatment with 50 μg rTSG-6 significantly enhanced bone formation compared to untreated and low-dose (10 µg) controls at 35 days post-injury. This effect was associated with increased osteoblast activity and reduced osteoclast activity. Moreover, rTSG-6 promoted M2 macrophage polarization and increased T-helper cell infiltration at the defect site three days after injury. In summary, TSG-6 enhances bone regeneration in critical-sized bone defects, through immunomodulation, particularly via M2 macrophage polarization, and stimulation of osteogenesis. These findings identify TSG-6 as a promising therapeutic candidate to improve bone repair, for example, in patients with osteoporosis, concomitant trauma or large bone defects.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-11-28
DOI
https://doi.org/10.3389/fimmu.2025.1712152
Primary Topic
Proteoglycans and glycosaminoglycans research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

TSG-6 promotes healing of critical-sized bone defects in mice

Mubashir Ahmad, Verena Fischer, Sandra Dieterich, Jasmin Maria Bülow et al.
Frontiers in Immunology
Proteoglycans and glycosaminoglycans research
article

TSG-6 promotes healing of critical-sized bone defects in mice

Mubashir Ahmad, Verena Fischer, Sandra Dieterich, Jasmin Maria Bülow, Karin Scharffetter‐­Kochanek, Melanie Haffner‐Luntzer, Anita Ignatius, Oliver Küppers, Christoph Kölbl
article en

Abstract

Tumor necrosis factor-stimulated gene 6 (TSG-6) is recognized for its anti-inflammatory and pro-regenerative properties in various inflammatory conditions, including peritonitis, arthritis, traumatic brain injury, and corneal as well as skin wound healing. However, its regenerative role in bone metabolism and repair remains largely unexplored. This study aimed to address this gap. We observed an increased expression of <i>Tnfaip6</i> (<i>Tsg-6</i>) during early osteogenic differentiation of murine mesenchymal stem cells (mMSCs). Silencing <i>Tnfaip6</i> significantly impaired osteogenic differentiation, as indicated by reduced alkaline phosphatase activity and downregulation of key osteogenic marker genes. RNA-seq analysis of <i>Tnfaip6</i>-deficient mMSCs revealed decreased expression of several genes that are critical for bone formation and healing, including matrix metallopeptidase 13, decorin, membrane metallopeptidase, and integrin binding sialoprotein. Conversely, gremlin 1, a known inhibitor of osteoblastogenesis, was significantly upregulated. To investigate the <i>in vivo</i> relevance, we assessed the effects of locally delivered recombinant TSG-6 (rTSG-6), embedded in a collagen gel, on bone regeneration in a 1.5 mm critical-sized femoral defect model in male C57BL/6J mice. Treatment with 50 μg rTSG-6 significantly enhanced bone formation compared to untreated and low-dose (10 µg) controls at 35 days post-injury. This effect was associated with increased osteoblast activity and reduced osteoclast activity. Moreover, rTSG-6 promoted M2 macrophage polarization and increased T-helper cell infiltration at the defect site three days after injury. In summary, TSG-6 enhances bone regeneration in critical-sized bone defects, through immunomodulation, particularly via M2 macrophage polarization, and stimulation of osteogenesis. These findings identify TSG-6 as a promising therapeutic candidate to improve bone repair, for example, in patients with osteoporosis, concomitant trauma or large bone defects.

Frontiers in ImmunologyVol. 16
Universität Ulm (DE), University Hospital Ulm (DE)
Openalex Percentile: Top 61%
Proteoglycans and glycosaminoglycans research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.